VOLUME 291 (2016) PAGES 21925–21944
PAGES 21931 AND 21933:
There were some errors in Tables 3 and 4 whereby some data values were increased by the addition of 10 units to each data point. These errors have now been corrected and do not affect the results or conclusions of this work.
TABLE 3.
Untreated |
Treated |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
pEC50a | Emaxb | pKac | log τd | n | pEC50a | Emaxb | pKac | log τd | n | |
RAMP1 | ||||||||||
CGRP | 9.66 ± 0.2 | 47.07 ± 2.2 | 9.43 ± 0.2 | −0.11 ± 0.04 | 9 | 9.65 ± 0.2 | 44.95 ± 2.2 | 9.33 ± 0.3 | −0.11 ± 0.07 | 6 |
AM | 7.93 ± 0.2 | 48.06 ± 2.5 | 7.67 ± 0.2 | −0.09 ± 0.05 | 9 | 8.14 ± 0.07 | 72.17 ± 1.7*** | 7.66 ± 0.2 | 0.36 ± 0.1** | 6 |
AM2 | 7.93 ± 0.2 | 46.10 ± 4.1 | 7.70 ± 0.2 | −0.11 ± 0.07 | 9 | 9.15 ± 0.1* | 72.15 ± 2.4*** | 8.56 ± 0.3 | 0.4 ± 0.1** | 6 |
RAMP2 | ||||||||||
CGRP | 9.00 ± 0.2 | 36.97 ± 2.4 | 8.82 ± 0.2 | −0.27 ± 0.05 | 9 | 8.25 ± 0.4 | 56.27 ± 1.4*** | 7.92 ± 0.2* | 0 0.1 ± 0.06** | 6 |
AM | 10.35 ± 0.1 | 56.33 ± 1.6 | 10.00 ± 0.1 | 0.07 ± 0.02 | 9 | 10.16 ± 0.07 | 56.07 ± 1.1 | 9.83 ± 0.2 | 0.07 ± 0.02 | 6 |
AM2 | 7.46 ± 0.2 | 36.61 ± 3.5 | 7.24 ± 0.2 | −0.29 ± 0.07 | 9 | 9.13 ± 0.1** | 56.05 ± 2.2*** | 8.84 ± 0.2** | 0.1 ± 0.06* | 6 |
RAMP3 | ||||||||||
CGRP | 7.75 ± 0.3 | 22.38 ± 2.6 | 7.64 ± 0.3 | −0.54 ± 0.07 | 8 | 8.90 ± 0.1* | 32.61 ± 1.5* | 8.74 ± 0.2* | −0.29 ± 0.06 | 7 |
AM | 8.98 ± 0.2 | 32.00 ± 1.5 | 8.83 ± 0.1 | −0.33 ± 0.03 | 8 | 9.10 ± 0.2 | 35.95 ± 2.2 | 8.94 ± 0.2 | −0.34 ± 0.05 | 7 |
AM2 | 9.10 ± 0.2 | 21.92 ± 1.7 | 9.08 ± 0.2 | −0.51 ± 0.06 | 8 | 8.74 ± 0.2 | 44.35 ± 2.7**** | 8.43 ± 0.1* | −0.07 ± 0.07*** | 7 |
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 μm forskolin stimulation in the presence of pertussis toxin treatment.
c The negative logarithm of the equilibrium disassociation constant for each ligand generated through use of the operational model of agonism (34).
d Log τ is the coupling efficiency parameter of each ligand.
TABLE 4.
Untreated |
Treated |
|||||
---|---|---|---|---|---|---|
pEC50a | Emaxb | n | pEC50a | Emaxb | n | |
RAMP1 | ||||||
CGRP | 9.88 ± 0.1 | 59.98 ± 1.1 | 5 | 9.87 ± 0.1 | 72.92 ± 2.3 | 5 |
AM | 8.13 ± 0.1 | 60.00 ± 3.1 | 5 | 8.03 ± 0.1 | 61.26 ± 2.6 | 5 |
AM2 | 8.74 ± 0.1 | 68.94 ± 1.2 | 5 | 8.78 ± 0.1 | 68.30 ± 1.6 | 5 |
RAMP2 | ||||||
CGRP | 8.00 ± 0.1 | 32.56 ± 1.0 | 5 | 7.88 ± 0.1 | 39.32 ± 1.7 | 5 |
AM | 9.39 ± 0.1 | 30.34 ± 0.8 | 5 | 9.38 ± 0.1 | 33.28 ± 1.2 | 5 |
AM2 | 8.57 ± 0.1 | 40.30 ± 1.5 | 5 | 8.58 ± 0.2 | 30.52 ± 2.0 | 5 |
RAMP3 | ||||||
CGRP | 8.42 ± 0.1 | 40.84 ± 0.6 | 5 | 8.38 ± 0.1 | 39.84 ± 1.0 | 5 |
AM | 9.63 ± 0.1 | 39.09 ± 1.2 | 5 | 9.49 ± 0.2 | 42.26 ± 1.6 | 5 |
AM2 | 8.01 ± 0.1 | 33.75 ± 1.5 | 5 | 7.79 ± 0.2 | 28.21 ± 2.4 | 5 |
a The negative logarithm of the agonist concentration required to produce a half-maximal response.
b The maximal response to the ligand expressed as a percentage of the maximal cAMP production as determined using 100 μm forskolin stimulation in the presence of PTX treatment.